SCHEMBL19699602

SCHEMBL19699602

CC(C)C(=O)Nc1ncc(OC[C@H](O)CO)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
MAPK1 P28482 1/20 0.39
CYP1A2 P05177 3/20 0.36
KMT2A Q03164 2/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
OPRK1 P41145 1/20 0.36
MEN1 O00255 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK5 Q00535 1/20 0.36
AR P10275 1/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19699611 1.00 TSHR (0.39) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL19706530 0.85 TSHR (0.44) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL19706544 0.85 TSHR (0.44) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL19699547 0.82 ALDH1A1 (0.50) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL19699559 0.82 ALDH1A1 (0.50) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL9813337 0.79 ADORA3 (0.42) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL19699543 0.79 RIOK2 (0.46) TSHRMAPK1MAPTPDE3BPDE3A
SCHEMBL19699577 0.79 KMT2A (0.44) TSHRMAPK1CYP1A2KMT2AADRB2
SCHEMBL19699541 0.79 RIOK2 (0.46) TSHRMAPK1MAPTPDE3BPDE3A
SCHEMBL19699570 0.79 KMT2A (0.44) TSHRMAPK1CYP1A2KMT2AADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362234-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-21 US disclosed
US-20170362234-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-21 US disclosed
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 TSHR 2418/4885MAPK1 1307/4885CYP1A2 2450/4885
US-20170362234-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 TSHR 2548/4885MAPK1 1369/4885CYP1A2 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.